• Home
  • About Us
  • Technology
  • Pipeline
  • Partnerships
  • News & Publications
HDT Bio

Intramuscular delivery of formulated RNA encoding six linked nanobodies is highly protective for exposures to three Botulinum neurotoxin serotypes. — Nature Scientific Reports

Jul 8, 2022 | Publications

Click here to view...

Pharmaceutical Technology: HDT Bio Receives Emergency Use Approval for Covid-19 Vaccine in India

Jun 30, 2022 | In the News

Click here to view...

GeekWire: COVID-19 Shots with Seattle Origins Reach Regulatory Milestones in South Korea, India

Jun 29, 2022 | In the News

Click here to view...

HDT Bio’s COVID-19 Vaccine Wins Regulatory Approval in India

Jun 29, 2022 | Press Releases

Next-generation RNA technology can be safer, more effective at lower doses than current mRNA COVID-19 vaccines. Proprietary LION™ delivery system provides stability at refrigerator temperature SEATTLE–(June 29, 2022) — Indian regulators have issued an...

Translational development of a tumor junction opening technology — Scientific Reports

May 11, 2022 | Uncategorized

Click here to view...
« Older Entries
Next Entries »

Recent Posts

  • Providence Swedish Neuroscience Institute (PSNI) Reaches Milestone in Reducing Global Burden of Glioblastoma
  • A New Approach to Treating Brain Cancer: HDT Bio Launches Canadian Clinical Program at McGill University
  • KING5 Seattle Healthlink Feature: Seattle-based group testing new immunotherapy approach to treat deadly form of brain cancer
  • HDT Bio and UTMB Receive MCDC Innovation Prototype Award for Advancing CCHF Vaccine from Lab to Phase 1 Clinical Trial
  • FDA Greenlights HDT Bio’s First-in-Class HDT-321 for the Prevention of Deadly Tick-Borne Disease

Recent Comments

No comments to show.

Privacy Policy

Terms of Use

©2024 HDT Bio

  • Follow
  • Follow